Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ranbaxy Launches Generic Aricept in the US
December 13, 2010
- Blopress Returns to Top Place in 3rd Qtr: IMS Japan
December 13, 2010
- M3 Acquires EMS Research in the UK
December 13, 2010
- Hospira Japan Launches Its 1st In-house Oncology Generics
December 13, 2010
- Memantine, Galantamine Recommended for Approval for AD
December 6, 2010
- Yasuchika Hasegawa to Be Appointed Chairman of Keizai Doyukai
December 6, 2010
- Takeda's SONIAS Recommended for Approval
December 6, 2010
- Kobayashi: Sales Up 0.8% despite Rebound from Boom for Flu-related Products in Previous Year
December 6, 2010
- Janssen's Stelara Recommended for Approval
December 6, 2010
- Cawachi: Sales, Profits Show Only Slight Increases
December 6, 2010
- 2-Week Limit on Prescription to Be Lifted for 4 ARB/CCB Combination Drugs
December 6, 2010
- Bayer Schering to Apply for Rivaroxaban in US, Europe by Year End: Chairman Andreas Fibig
December 6, 2010
- PMDA to Upgrade Reviewers' Scientific Expertise
December 6, 2010
- Astellas to Increase Market Share for Vesicare with OD Tablets
December 6, 2010
- No. of Generics Listed in November Announced by Korosho
December 6, 2010
- Inavir Can Complete Treatment with a Single Dose: Daiichi Sankyo
December 6, 2010
- PMDA's Project Team Proposes East Asian Central Review System
December 6, 2010
- Novartis to Globally Apply for 13 Drugs in 2011, 9 in 2012
December 6, 2010
- Approval of Two Implantable Heart Assist Systems Recommended
December 6, 2010
- Toho Expects One Point Reduction in Yakkasa on Full-Year Basis
December 6, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…